Phase II study of docetaxel in patients with relapsed or refractory malignant lymphoma |
| |
| Authors: | Zekri J M Hough R E Davies J M Molife R Hancock B W Lorigan P C |
| |
| Institution: | Cancer Research Centre, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ, UK. jmzekri@hotmail.com |
| |
| Abstract: | We report the activity and toxicity of docetaxel in 12 evaluable heavily pretreated patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. In all, 42% achieved a partial response, 25% achieved stable disease. Median duration of response was 16 (10-21) weeks. The median overall survival was 70 (9-178) weeks and for responders it was 120 (22-178) weeks. One patient developed one episode of neutropenic sepsis. Docetaxel has limited activity in this group of patients. |
| |
| Keywords: | docetaxel non-Hodgkin''s lymphoma Hodgkin''s disease |
| 本文献已被 PubMed 等数据库收录！ |
